DOCSLIB.ORG

Synthetic Opioids, Other Substances, and Stimulants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Synthetic Opioids, Other Substances, and Stimulants UR Medicine Recovery Center of Excellence Synthetic Opioids, Other Substances, and Stimulants HRSA Rural Communities Opioid Response Program (RCORP) Rural Center of Excellence in Substance Use Disorder October 16, 2020 UR Medicine Recovery Center of Excellence: Service Area • Partnering with 23 counties in Appalachian KY, OH, NY, and WV • Support and resources for rural communities across the U.S. 2 UR Medicine Recovery Center of Excellence Reducing morbidity, mortality & other harmful effects of substance use disorder (SUD)—particularly from synthetic opioids—by combining CDC evidence-based practices1 with emerging best practices from Appalachian partners to provide new rural-focused resources and hands-on technical assistance Primary Academic Care Naloxone MOUD Behavioral Detailing Provision Distribution Telemedicine Health of MOUD Bridge Assessment Program Officer ED & SUD Treatment Ecosystem of Behavioral Provider Recovery Health Partnership Care Manager in Primary Care 3 Synthetic Opioids, Other Substances, and Stimulants 1. Understand synthetic opioids as drivers of opioid overdose mortality 2. Understand the next wave of stimulant use 3. Learn about resources for understanding new trends in drug use and novel psychoactive substances (NPS) 4 The Overdose Epidemic Source: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. (Last reviewed 2020, March 19). Understanding the epidemic. 5 The Overdose Epidemic & COVID-19 • The sense of connection fostered in recovery programs can be an important factor in promoting recovery from opioid use disorder. Connection with others becomes difficult when people are advised to stay home, wear masks, and practice physical distancing. Many states have already reported increases in opioid overdose.2 • Overdose Detection Mapping Application Program (ODMAP) is a syndromic surveillance system that provides near real-time suspected overdose data nationally. • In the time following 3/19/20, 62% of participating counties experienced an increase in overdose submissions with an observed 18% increase in suspected overdose submissions.3 Source for figure: ODMAP. Cited in Washington Post (2020, July 1). 6 Synthetic Opioids as Drivers of Opioid Overdose Deaths Source: CDC. (Last reviewed 2020, March 19). Opioid data analysis and resources. 7 Synthetic Opioids In 2018, 67% of opioid-related deaths involved synthetic opioids.4 Making naloxone available for opioid overdose reversal is one of the CDC evidence-based practices.5 “Higher doses of naloxone are needed in the synthetic opioid era.”6 Source for figure: CDC. (Last reviewed 2020, March 19). Opioid data analysis and resources. 8 Fentanyl Source for figures: CDC. (Last reviewed 2020, March 19). Synthetic opioid overdose data. 9 Fentanyl Analogs & Novel Synthetic Opioids • Fentanyl, alfentanil, remifentanil, sufentanyl— used in anesthesia • Carfentanil—used in large animal anesthesia; the most potent approved opioid drug • 10,000x more potent than morphine • 30-100x more potent than fentanyl • MANY other fentanyl analogs7,8 • Other novel synthetic opioids • U-47700, U-48800, U-50488, U-51754, W-18 • Isotonitazene—reported in U.S. in 20199 Source for figure: U.S. Drug Enforcement Administration. (2019). National drug threat assessment, p. 11. 10 Stimulant Use: The Next Wave? Overdose Deaths Involving Stimulants Have Increased Rates of overdose deaths involving synthetic opioids other than methadone, cocaine, and psychostimulants with abuse potential (e.g. methamphetamine) all increased from 2017 to 2018.10 • Drug overdose deaths involving synthetic opioids increased by 10%, from 9.0 per 100,000 in 2017 to 9.9 in 2018. • Deaths involving cocaine more than tripled (from 1.4 to 4.5). • Deaths involving psychostimulants increased nearly five-fold (from 0.8 to 3.9). Keep in mind that there are no FDA-approved medications for stimulant use disorder. 11 Opioids Driving Increase in Cocaine-Involved Overdose • Data suggest that the increase in cocaine-involved overdose deaths from 2015 to 2018 was driven by opioids. • The increase in cocaine overdose deaths from 2015 to 2018 was mirrored by a corresponding increase in the rate of overdose deaths involving both cocaine and fentanyl. • During this time period, we also saw a substantial increase in the rate of overdose deaths involving cocaine and fentanyl, without heroin. Cocaine overdose deaths involving fentanyl but no heroin, are a proxy for deaths where fentanyl might have been present in the cocaine product. Source for figure: NDEWS. (2020). New York City SCS Drug Use Patterns & Trends, p. 8. 12 Methamphetamine 2015-2018 • During 2015–2018, an estimated 1.6 million U.S. adults aged ≥18 years, on average, reported past-year methamphetamine use. • 52.9% had a methamphetamine use disorder. • 22.3% reported injecting methamphetamine within the past year. • Co-occurring substance use and mental illness were common among those who used methamphetamine within the past year.11 Source for figure: National Surveys on Drug Use and Health. 2015-2018, using 2010 U.S. Census-based population estimates. Cited in Jones et al. (2020). 13 Methamphetamine & Overdose in the West Source: NCHS National Vital Statistics System. Cited in AP News (2019, October 25). 14 Removals of Methamphetamine by State in Kilograms, 2018 Source: DEA. (2019). 2019 National drug threat assessment, p. 44. 15 New Trends in Drug Use and Other Novel Psychoactive Substances (NPS) • New NPS being reported each year, and the market for these substances changes from year to year. • Synthetic cannabinoids (K2, Spice) • Synthetic cathinones (“Bath salts”) • Drug trends and fads: which ones are a real problem, and which are hype or urban legend? • How can we follow and make sense of NPS and other drug trends? 16 Resources for Understanding New Trends in Drug Use and Novel Psychoactive Substances (NPS) • CDC: Center for Disease Control • SAMHSA: Substance Abuse & Mental Health Services Administration—NSDUH, TIPS • NDEWS: National Drug Early Warning System • DEA: Drug Enforcement Administration • NFLIS: National Forensic Laboratory Information System • ODMAP: Overdose Detection Mapping Application Program • MTF: Monitoring the Future • NIDA: National Institute on Drug Abuse—DrugFacts series 17 NDEWS: National Drug Early Warning System • Funded by NIDA • Currently involves Univ. of Florida, NYU & Florida Atlantic University • Subscribe to NDEWS Weekly Briefings Source for figure: About NDEWS. (Accessed 2020, October 2.) 18 NDEWS Web Monitoring “AP-238 is a derivative of Bucinnazine (AP-237, 1- butyryl-4-cinnamyl-piperazine), which has been used clinically in China and is currently listed for purchase on popular web-based drug marketplaces. AP-238 was recognized as a potentially relevant drug keyword through algorithmic monitoring of communities dedicated to drug discussion on the social media platform Reddit. Mentions of ‘AP-238’ in the past 18 months across ~70 drug-oriented subreddit communities were quantified and aggregated by month to obtain a relative metric of discussion over time.” Source: NDEWS Weekly Briefing, Issue 5. (2020, September 25). 19 International Resources • WHO: World Health Organization • UNODC: United Nations Office on Drugs and Crime • EMCDDA: European Monitoring Centre for Drugs and Drug Addiction 20 Most Commonly Reported Synthetic Cannabinoids • National Forensic Laboratory Information System (NFLIS), part of the DEA • 5F-MDMB-PICA=methyl 2-(1-(5- fluoropentyl)-1H-indole-3- carboxamido)-3,3- dimethylbutanoate Source: DEA, National Forensic Laboratory Information System. (2020). NFLIS-Drug 2019 Annual Report, p. 18. 21 Synthetic Cannabinoids: Number of Exposure Calls to the American Association of Poison Control Centers for Synthetic Cannabinoids, 2010-2018 Source: DEA. (2019). 2019 National drug threat assessment, p. 94. 22 Synthetic Cathinones • Stimulant properties, usually sold as pills or capsules, but can also be smoked or snorted • In 2017, there were 10,693 reports of synthetic cathinones to NFLIS, a 36% increase over the 7,879 reports in 2016. • The most frequently reported synthetic cathinone in 2017 was N-ethylpentylone at 60.49%. • The second most common synthetic cathinone was dibutylone at 10.9%. • DEA published a temporary scheduling order controlling N-ethylpentylone. in Schedule I of the Controlled Substances Act (CSA) in August 2018. Dibutylone is a positional isomer of pentylone, a Schedule I substance and thus is in Schedule I of the CSA.12 23 Other Drug Use Trends • Phenibut • Hallucinogens • Social media “challenges” 24 Phenibut • β-phenyl-γ-aminobutyric acid (a GABA Number of human exposure cases related to phenibut use reported to poison centers, by year—National Poison Data receptor agonist) System, United States, January 2009–December 2019 • Drug developed in Russia in the 1960s for use as an antianxiety medication with cognitive enhancement properties • Available online and in health food stores • Adverse consequences of overuse: somnolence, respiratory depression, withdrawal symptoms13 Source for figure: Graves et al. (2020). 25 There are many sides to hallucinogen use 1. Hallucinogen use disorder 2. Spiritual uses for some hallucinogens 3. Research on potential medical use 26 Hallucinogen Use Disorder DSM-5 divides hallucinogen use into 2 categories: 1. Phencyclidine Use Disorder: Phencyclidine and phencyclidine-like compounds (ketamine, cyclohexamine, dizocilipine) 2. Other Hallucinogen Use Disorder Hallucinogen persisting perception disorder 27 Hallucinogens:
Load more

Recommended publications
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
    [Show full text]
  • Phenibut Overdose in Combination with Fasoracetam: Emerging Drugs of Abuse
    Open Access Journal of Clinical Intensive Care and Medicine Case Report Phenibut Overdose in Combination ISSN with Fasoracetam: Emerging Drugs 2639-6653 of Abuse Cristian Merchan1*, Ryan Morgan1, John Papadopoulos1,2 and David Fridman2 1Department of Pharmacy, New York University Langone Medical Center, New York, USA 2New York University School of Medicine, New York, USA *Address for Correspondence: Dr. Cristian INTRODUCTION D Merchan, Pharm.D, BCCCP, Critical Care Pharmacotherapist, Department of Pharmacy, The widespread availability of non-traditional dietary supplements and New York University Langone Medical Center, pharmacologically active substances via the Internet continues to introduce New York, USA, Tel: 516-263-1671; Email: [email protected] mechanisms for inadvertent toxidromes not commonly seen. Consumers are virtually unrestricted in their ability to acquire products purporting augmentation of normal Submitted: 25 October 2016 Approved: 15 December 2016 physiology for the purposes of enhancement, recreation, and/or potential abuse. The Published: 17 December 2016 safety proiles at standard or toxic doses remain largely unknown for many agents that Copyright: 2016 Merchan et al. This is an can be purchased electronically. We report a case of mixed toxicity related to phenibut open access article distributed under the and fosaracetam, both of which are readily available for consumer purchase from Creative Commons Attribution License, which online retailers. Written and verbal consent was obtained for this case presentation. permits unrestricted use, distribution, and reproduction in any medium, provided the CASE REPORT original work is properly cited. Keywords: Nootropic; GABA agonist; Drug of A 27-year-old male with a past medical history of anxiety was discovered abuse; Dietary supplement; Alternative medicine unresponsive on the sidewalk.
    [Show full text]
  • Conjugation of Tryptamine to Biologically Active Carboxylic Acids in Order to Create Prodrugs
    ISSN 2380-5064 | The Arsenal is published by the Augusta University Libraries | http://guides.augusta.edu/arsenal Volume 4, Issue 1 (2021) Special Edition Issue CONJUGATION OF TRYPTAMINE TO BIOLOGICALLY ACTIVE CARBOXYLIC ACIDS IN ORDER TO CREATE PRODRUGS Colin Miller, Jr. and Iryna O. Lebedyeva Citation Miller, C., Jr., & Lebedyeva, I. O. (2021). Conjugation of tryptamine to biologically active carboxylic acids in order to create prodrugs. The Arsenal: The Undergraduate Research Journal of Augusta University, 4(1), 26. http://doi.org/10.21633/issn.2380.5064/s.2021.04.01.26 © Miller, Jr. and Lebedyeva 2021. This open access article is distributed under a Creative Commons Attribution NonCommercial-NoDerivs 2.0 Generic License (https://creativecommons.org/licenses/by-nc-nd/2.0/). Conjugation of Tryptamine to Biologically Active Carboxylic Acids in Order to Create Prodrugs Presenter(s): Colin Miller, Jr. Author(s): Colin Miller Jr. and Iryna O. Lebedyeva Faculty Sponsor(s): Iryna O. Lebedyeva, PhD Affiliation(s): Department of Chemistry and Physics (Augusta Univ.) ABSTRACT A number of blood and brain barrier penetrating neurotransmitters contain polar functional groups. Gamma-aminobutyric acid (GABA) is an amino acid, which is one of the primary inhibitory neurotransmitter in the brain and a major inhibitory neurotransmitter in the spinal cord. Antiepileptic medications such as Gabapentin, Phenibut, and Pregabalin have been developed to structurally represent GABA. These drugs are usually prescribed for the treatment of neuropathic pain. Since these drugs contain a polar carboxylic acid group, it affects their ability to penetrate the blood and brain barrier. To address the low bioavailability and tendency for intramolecular cyclization of Gabapentin, its less polar prodrug Gabapentin Enacarbil has been approved in 2011.
    [Show full text]
  • Moves to Amend HF No. 2128 As Follows:​ Delete Everything After
    04/05/21 10:32 am ​ HOUSE RESEARCH RC/MV H2128DE1​ 1.1 .................... moves to amend H.F. No. 2128 as follows:​ 1.2 Delete everything after the enacting clause and insert:​ 1.3 "ARTICLE 1​ 1.4 DHS HEALTH CARE PROGRAMS​ 1.5 Section 1. [62A.002] APPLICABILITY OF CHAPTER.​ 1.6 Any benefit or coverage mandate included in this chapter does not apply to managed​ 1.7 care plans or county-based purchasing plans when the plan is providing coverage to state​ 1.8 public health care program enrollees under chapter 256B or 256L.​ 1.9 Sec. 2. Minnesota Statutes 2020, section 62C.01, is amended by adding a subdivision to​ 1.10 read:​ 1.11 Subd. 4. Applicability. Any benefit or coverage mandate included in this chapter does​ 1.12 not apply to managed care plans or county-based purchasing plans when the plan is providing​ 1.13 coverage to state public health care program enrollees under chapter 256B or 256L.​ 1.14 Sec. 3. Minnesota Statutes 2020, section 62D.01, is amended by adding a subdivision to​ 1.15 read:​ 1.16 Subd. 3. Applicability. Any benefit or coverage mandate included in this chapter does​ 1.17 not apply to managed care plans or county-based purchasing plans when the plan is providing​ 1.18 coverage to state public health care program enrollees under chapter 256B or 256L.​ 1.19 Sec. 4. [62J.011] APPLICABILITY OF CHAPTER.​ 1.20 Any benefit or coverage mandate included in this chapter does not apply to managed​ 1.21 care plans or county-based purchasing plans when the plan is providing coverage to state​ 1.22 public health care program enrollees under chapter 256B or 256L.​ Article 1 Sec.
    [Show full text]
  • 4Th Quarter 2020 DEA
    QUARTERLY REPORT 4th Quarter – 2020 U.S. Department of Justice Drug Enforcement Administration Diversion Control Division Drug and Chemical Evaluation Section Drug Enforcement Administration – Toxicology Testing Program Contents Introduction ............................................................ 3 Summary ................................................................. 4 NPS Discovered via DEA TOX ................................. 5 New Psychoactive Substances ............................... 6 Traditional Illicit Drugs ........................................... 8 Prescription and Over the Counter Drugs ............. 9 Contact Information ............................................. 10 2 | Page 4th Quarter Report – 2020 Drug Enforcement Administration – Toxicology Testing Program Introduction The Drug Enforcement Administration’s Toxicology Testing Program (DEA TOX) began in May 2019 as a surveillance program aimed at detecting new psychoactive substances within the United States. In response to the ongoing synthetic drug epidemic, the Drug Enforcement Administration (DEA) awarded a contract with the University of California at San Francisco (UCSF) to analyze biological samples generated from overdose victims of synthetic drugs. In many cases, it can be difficult to ascertain the specific substance responsible for the overdose. The goal of DEA TOX is to connect symptom causation to the abuse of newly emerging synthetic drugs (e.g. synthetic cannabinoids, synthetic cathinones, fentanyl-related substances, other hallucinogens, etc.).
    [Show full text]
  • Fragmentation Pathways of Odd- and Even-Electron N-Alkylated Synthetic Cathinones
    International Journal of Mass Spectrometry 453 (2020) 116354 Contents lists available at ScienceDirect International Journal of Mass Spectrometry journal homepage: www.elsevier.com/locate/ijms Fragmentation pathways of odd- and even-electron N-alkylated synthetic cathinones * J. Tyler Davidson, PhD a, Zachary J. Sasiene, BS b, Glen P. Jackson, Ph.D. a, b, a Department of Forensic and Investigative Science, West Virginia University, Morgantown, WV, 26506-6121, USA b C. Eugene Bennett Department of Chemistry, West Virginia University, Morgantown, WV, 26506-6121, USA article info abstract Article history: Three ionization techniques, isotopic labeling, high-resolution mass spectrometry (HRMS) and multi- Received 19 March 2020 stage mass spectrometry (MSn) were used to analyze a series of N-alkylated synthetic cathinone de- Received in revised form rivatives and gain a deeper understanding of their fragmentation behavior during mass spectrometric 17 April 2020 analysis. The compounds analyzed represent 15 unique structures with common substitutions to the core Accepted 18 April 2020 synthetic cathinone structure, including substitutions to the aromatic ring and the number and types of Available online 23 April 2020 N-alkyl functionalities. The analytical techniques employed include gas chromatography-electron ioni- zation-mass spectrometry (GC-EI-MS), electrospray ionization-tandem mass spectrometry (ESI-MS/MS) with HRMS and direct analysis in real time tandem mass spectrometry (DART-MS/MS) with HRMS. These techniques cover a variety of forensic applications, including seized drug analysis, toxicological analysis and screening analysis, in local, state and federal laboratories. For collision-induced dissociation (CID) of protonated precursors, the spectra of 2 and 3 amines showed evidence for charge-remote and charge- directed fragmentation mechanisms.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Written Witness Statement for U.S. Sentencing Commission's Public
    STATEMENT OF TERRENCE L. BOOS, PH.D. SECTION CHIEF DRUG AND CHEMICAL EVALUATION SECTION DIVERSION CONTROL DIVISION DRUG ENFORCEMENT ADMINISTRATION and CASSANDRA PRIOLEAU, PH.D. DRUG SCIENCE SPECIALIST DRUG AND CHEMICAL EVALUATION SECTION DIVERSION CONTROL DIVISION DRUG ENFORCEMENT ADMINISTRATION - - - BEFORE THE UNITED STATES SENTENCING COMMISSION - - - HEARING ON SENTENCING POLICY FOR SYNTHETIC DRUGS - - - OCTOBER 4, 2017 WASHINGTON, D.C. 1 Introduction New Psychoactive Substances (NPS) are substances trafficked as alternatives to well- studied controlled substances of abuse. NPS have demonstrated adverse health effects such as paranoia, psychosis, and seizures to name a few. Cathinones, cannabinoids, and fentanyl-related substances are the most common NPS drug classes encountered on the illicit drug market, all with negative consequences for the user to include serious injury and death. Our early experience saw substances being introduced from past research efforts in an attempt to evade controls. This has evolved to NPS manufacturers structurally altering substances at a rapid pace with unknown outcomes to targeting specific user populations. These substances represent an unprecedented level of diversity and consequences. Due to clandestine manufacture and unscrupulous trafficking, the user is at great risk. A misconception exists that these substances carry a lower risk of harm In reality, published reports from law enforcement, emergency room physicians and scientists, accompanied with autopsies from medical examiners, have clearly demonstrated the harmful and potentially deadly consequences of using synthetic cathinones. These substances are introduced in an attempt to circumvent drug controls and the recent flood of NPS remains a challenge for law enforcement and public health. The United Nations Office on Drugs and Crime reported over 700 NPS encountered.1 The manufacturers and traffickers make minor changes in the chemical structure of known substances of abuse and maintain the pharmacological effect.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • Newer Unregulated Drugs Look-Up Table
    Newer Unregulated Drugs Look-up Table List Name Chemical Name/AKA Type of drug Notes Stimulant Regulation under MDA (Sch. 1 or TCDO) Stimulant/Hallucinogen Regulation under MDA (Sch. 2-5) Hallucinogen Regulated by PSA Depressant Exempt Cannabinoid Uncertain/requires clarification 1P-LSD 1-propionyl-lysergic acid diethylamide Hallucinogen An LSD analogue that side-stepped MDA and was on sale as an NPS; now covered by the PSA. 2-AI 2-Aminoindane Stimulant, amphetamine analogue Reported in the UK in 2011 by the Forensic Early 2-MAI N-methyl-2-Aminoindane Warning System (FEWS). Had been on sale via number MMAI of online stores; covered by PSA. 2-MeO-ketamine Methoxyketamine Related to methoxetamine so a relative Believed to have been made a CD at the same time as Methoxieticyclidine of ketamine – i.e. a dissassociative Methoxetamine anaesthetic hallucinogen 2C-B-BZP (1-(4-bromo-2,5- Piperazine family; stimulant Class B dimethoxybenzyl)piperazine) 2-DPMP Desoxypipadrol stimulant Strong and long acting stimulant; reported duration of 2-diphenylmethylpiperidine effect 24-28hrs or more and effective at very low doses. Had been on sale in the UK and cropped up in branded “Ivory Wave” and in other compounds. Linked to fatalities. Class B, Sch1. 2-NE1 APICA Synthetic cannabinoid receptor agonist 3rd generation SCRA. Covered by PSA SDB-001 N-(1-adamantyl)-1-pentyl-1H-indole-3- carboxamide 3-FPM Phenzacaine Stimulant, euphoriants Sibling of the controlled drug Phenmetrazine. Emerged PAL-593 2015. Covered by PSA 2-(3-fluorophenyl)-3-methylmorpholine 3-hydroxyphenazepam Benzo, GABA-nergic PSA 3-MeO-PCE (3-methoxyeticyclidine) Related to methoxetamine so a relative Probably regulated under the same clause that made of ketamine – i.e.
    [Show full text]
  • Case: 1:18-Cr-00474-JRA; Zheng ECF Filed Indictment
    Case: 1:18-cr-00474-JRA Doc #: 1 Filed: 08/17/18 1 of 83. PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION UNITED STATES OF AMERICA, ) INDICTMENT Plaintiff, ~ JUDGE PO V. ~ CASE10; 18 CR ) Title 21, Sections 33l(a), FUJINO ZHENG, ) 333(b)(7), 35l(d), 841(a)(l), aka, GORDON JIN, ) (a)(2), (b)(l)(A), (b)(l)(C), (h), aka, MR. JIN, ) 843(c)(2)(A), 846, 848, 853, aka, GORDON ZHENG, ) 952(a), 959(a), 960(a)(l) and (3), aka, JINXINXIN, ) (b)(1 ), (b )(3), 963, and 970, aka, FU JING ZHENG, ) Title 18, Sections 1956(a)(2), (h), aka, DENG GAO, ) and 2, GUANGHUA ZHENG, ) United States Code aka, GUANG HUA ZHENG, ) ) Defendants. ) ) COUNT 1 (Conspiracy to Manufacture, Distribute, and Possess with the Intent to Distribute Controlled Substances and Controlled Substance Analogues Resulting in Death, 21 U.S.C. §§ 841(a)(l), (b)(l)(A), (b)(l)(C), all in violation of 21 U.S.C. § 846) The Grand Jury charges: 1. From on or about January 1, 2008 to the Present, the exact dates unknown to the Grand Jury, in the Northern District of Ohio, Eastern Division, the People's Republic of China, and elsewhere, Defendants FUJINO ZHENG, aka GORDON JIN, aka MR. JIN, aka GORDON ZHENG, aka JINXINXIN, aka FU JING ZHENG, aka DENG GAO; GUANGHUA ZHENG, aka GUANG HUA ZHENG; Guangfu Z.; Guifeng C.; Songyan J.; Longbao Z.; Qinghua Y., aka Jason Yen; Lynn X.; Leroy S.; (individuals whose names are known to the Grand Jury); Global United Biotechnology; Global United Holdings; Global Biotech, Inc.; Global Holdings, Inc.; Top Lab RC; Global RC; Golden Chemicals; Cambridge Chemicals; Wonda Science; OneChem; Case: 1:18-cr-00474-JRA Doc #: 1 Filed: 08/17/18 2 of 83.
    [Show full text]
  • 2016-11-BMF-83 Antidepressants
    Antidepressants BMF 83 - Antidepressants BMF 83 - Antidepressants Depression is a common psychiatric disorder impacting millions of people worldwide. It is caused by an imbalance of chemicals 1 in the brain, namely serotonin and noradrenaline . Everyone experiences highs and lows, but depression is characterised by 2 persistent sadness for weeks or months . With depression there is lasting feeling of hopelessness, often accompanied by anxiety. Sufferers lose interest in things that they previously enjoyed, and experience bouts of tearfulness. Rational thinking and decision 2 making are impacted. Physical manifestations include tiredness, insomnia, loss of appetite and sex drive, aches and pains . At its worst depression can cause the sufferer to feel suicidal. Depression is usually treated with a combination of counselling and drug therapy. There is also evidence that exercise can help depression. Most people with moderate or severe depression benefit from antidepressant medication. There are a wide range of 3 antidepressants on the market, which can be broadly divided according to mechanism of action ; • Selective serotonin reuptake inhibitors (SSRIs) • Serotonin-norepinephrine reuptake inhibitors (SNRIs) • Serotonin modulator and stimulators (SMSs) • Serotonin antagonist and reuptake inhibitors (SARIs) • Norepinephrine reuptake inhibitors (NRIs or NERIs) • Tetracyclic antidepressants (TeCAs) • Tricyclic antidepressants (TCAs) • Monoamine oxidase inhibitors (MAOIs) www.chiron.no | E-mail: [email protected] | Tel.: +47 73 87 44 90 | Fax.: +47 73 73 87 44 99 | BMF 83 p.1/8 , 10_16 BMF 83 - Antidepressants BMF 83 - Antidepressants 1 Today the most common first choice of medication is a SSRI , i.e. Citalopram, Escitalopram, Fluvoxamine, Paroxetine, Sertraline, Fluoxetine. Antidepressants are not addictive, but can result in withdrawal symptoms when therapy is stopped.
    [Show full text]